Other News To Note
• Dako, of Glostrup, Denmark, part of Agilent Technologies Co., received FDA approval for the addition of Kadcyla (ado-trastuzumab emtansine) to the labeling of two Dako companion diagnostic assays. Kadcyla is marketed by Roche AG unit Genentech Inc., of South San Francisco.